Alnylam Pharmaceuticals, Inc. $ALNY Shares Newly Acquired by TB Alternative Assets Ltd.

TB Alternative Assets Ltd. acquired a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 4,360 shares of the biopharmaceutical company’s stock, valued at approximately $1,076,000. Alnylam Pharmaceuticals makes up about 0.2% of TB Alternative Assets Ltd.’s investment portfolio, making the stock its 25th biggest position.

Several other hedge funds and other institutional investors also recently bought and sold shares of ALNY. MV Capital Management Inc. acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at approximately $25,000. Toth Financial Advisory Corp acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth approximately $25,000. Burkett Financial Services LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth approximately $37,000. CoreCap Advisors LLC grew its position in shares of Alnylam Pharmaceuticals by 744.4% during the third quarter. CoreCap Advisors LLC now owns 152 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 134 shares in the last quarter. Finally, Keating Financial Advisory Services Inc. bought a new stake in shares of Alnylam Pharmaceuticals in the second quarter worth $42,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY opened at $234.03 on Friday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $197.81 and a 52 week high of $495.55. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75. The firm has a market cap of $31.32 billion, a price-to-earnings ratio of 43.50 and a beta of 0.28. The stock has a 50 day moving average of $239.10 and a 200-day moving average of $274.64.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%. The business had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.32 billion. During the same period in the prior year, the company posted ($0.51) EPS. The business’s revenue was up 66.9% compared to the same quarter last year. As a group, analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.68 EPS for the current year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Bryan Supran sold 1,758 shares of the business’s stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $226.88, for a total transaction of $398,855.04. Following the completion of the sale, the executive vice president owned 12,807 shares in the company, valued at $2,905,652.16. The trade was a 12.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals News Summary

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: UBS initiated coverage of Alnylam with a Buy rating and a $354 price target, implying substantial upside from the stock’s recent level. The new coverage may be supporting investor sentiment. Alnylam third-quarter 2026 financial results webcast
• Positive Sentiment: Analysts continue to point to Alnylam’s pipeline as a potential source of longer-term growth, which could help rebuild confidence after the company’s guidance reduction. UBS’s target is also well above recent trading levels. Analysts offer insights on Alnylam
• Neutral Sentiment: Alnylam plans to webcast a conference call covering its third-quarter 2026 financial results. The upcoming update could provide clarity on product demand, guidance and the outlook for AMVUTTRA, making it a near-term catalyst for the stock. Alnylam third-quarter 2026 financial results webcast
• Negative Sentiment: Citigroup lowered its price target to $320 from $340, while Wells Fargo reduced its target to $253 from $256 and maintained an Equal Weight rating. Although Citi retained a Buy rating, the reductions reflect more cautious expectations. Alnylam analyst price target changes
• Negative Sentiment: Recent coverage highlights lingering concerns about the guidance cut and slower-than-expected AMVUTTRA demand growth. Those issues have weighed on the stock and remain a risk until Alnylam demonstrates renewed commercial momentum. Alnylam bulls and bears after guidance cut

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Royal Bank Of Canada cut their price target on shares of Alnylam Pharmaceuticals from $350.00 to $345.00 and set an “outperform” rating on the stock in a report on Thursday, October 8th. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, July 31st. Morgan Stanley decreased their price objective on shares of Alnylam Pharmaceuticals from $400.00 to $300.00 and set an “equal weight” rating for the company in a report on Friday, July 31st. Stifel Nicolaus dropped their target price on shares of Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating for the company in a research report on Friday, July 31st. Finally, Oppenheimer cut their target price on shares of Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating on the stock in a research note on Friday, July 31st. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $364.95.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi), a biological process that can selectively reduce the production of disease-causing proteins. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include ONPATTRO (patisiran), an RNAi therapy for hereditary transthyretin-mediated amyloidosis with polyneuropathy; GIVLAARI (givosiran), for acute hepatic porphyria; OXLUMO (lumasiran), for primary hyperoxaluria type 1; and AMVUTTRA (vutrisiran), for transthyretin-mediated amyloidosis.